MiNK Therapeutics is focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The lead product candidate, agenT-797, is in Phase 2 clinical development for critical pulmonary immune failure (severe pneumonia and moderate-to-severe acute hypoxemic respiratory failure) and refractory solid tumor cancers. Phase 1/2 data for agenT-797 in mechanically ventilated patients with severe viral ARDS showed >70% 30-day survival (80% in the VV-ECMO subgroup) compared to ~10% in contemporaneous controls. Phase 1 clinical trial data for agenT-797 in 34 patients with refractory solid tumors demonstrated durable clinical activity, including complete remissions and long-term survivors (>23+ years), with a median overall survival of approximately 23 months in combination with anti-PD-1. Case reports published in Oncogene (January 2024 and 2025) detailed a durable partial response in gastric cancer and a complete remission in metastatic testicular cancer following agenT-797 treatment. A Phase 2 investigator-sponsored trial for agenT-797 in combination with Agenus' botensilimab and balstilimab, plus ramucirumab and paclitaxel, for advanced esophageal, gastric, or GEJ adenocarcinoma, initiated in February 2024. Early translational data from the Phase 2 combination study (AACR IO 2025) showed robust immune activation, including elevated interferon-gamma levels, rapid tumor infiltration, CD8+ T-cell activation, and immune reprogramming. Preclinical engineered iNKT programs, MiNK-413 (BCMA-CAR-iNKT) and MiNK-215 (FAP-CAR-iNKT), are advancing, with IND-enabling studies underway for MiNK-215. The company reported a net loss of $12.5 million for the year ended December 31, 2025, compared to $10.8 million in 2024. An accumulated deficit of $156.7 million was reported as of December 31, 2025. Cash and cash equivalents stood at $13.4 million as of December 31, 2025. The independent registered public accounting firm included an explanatory paragraph regarding the company's ability to continue as a going concern. The company raised $17.5 million in net proceeds from an At Market Issuance Sales Agreement in 2025 and an additional $3.0 million from January 1, 2026, through March 27, 2026. A $5.0 million related party note, plus accrued interest of $179,444, was repaid in full in January 2026.